(INN) is an oral, thienopyridine-class antiplatelet agent used to inhibit blood clots in coronary artery disease, peripheral vascular disease
, cerebrovascular disease, and to prevent myocardial infarction
(heart attack) and stroke. It is marketed by Bristol-Myers Squibb and Sanofi under the trade name Plavix
. The drug works by irreversibly inhibiting a receptor called P2Y12
, an adenosine diphosphate (ADP) chemoreceptor
on platelet cell membranes
. Adverse effects include bleeding and thrombotic thrombocytopenic purpura.